» Articles » PMID: 36979255

Lurasidone Augmentation of Clozapine in Schizophrenia-Retrospective Chart Review

Overview
Journal Brain Sci
Publisher MDPI
Date 2023 Mar 29
PMID 36979255
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of our study was to evaluate the effectiveness of lurasidone augmentation of clozapine in treatment-resistant schizophrenia (SZ) in a retrospective chart review. From the medical records of 916 SZ patients, we identified 16 individuals treated with a combination of clozapine and lurasidone. The detailed clinical data are described separately for each patient. We compared the Clinical Global Impression-Severity (CGI-S) scores between three points of observation: before the treatment and one month and two months after its initiation. CGI Improvement (CGI-I) scores were used to evaluate the treatment response between the first and last points of observation. The vast majority of patients (14/16, 87.5%) responded to lurasidone augmentation of clozapine (CGI-I scores 1 or 2). Therapeutic effects were observable after 3-12 weeks of treatment (median 6 (4-6)). A reduction in CGI-S scores was observed after the first month of observation. There was an observable reduction in positive, depressive and anxiety symptoms, as well as an improvement in psychosocial functioning. Two patients discontinued treatment due to side effects. Our study suggests that lurasidone augmentation of clozapine may lead to improvements in a broad range of SZ symptom dimensions.

Citing Articles

Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence.

Mora F, Gomez Sanchez-Lafuente C, De Iceta M, Roset C, Cardenas A, Perez D Front Psychiatry. 2025; 15:1506142.

PMID: 40013022 PMC: 11862477. DOI: 10.3389/fpsyt.2024.1506142.


Drugs with glutamate-based mechanisms of action in psychiatry.

Chrobak A, Siwek M Pharmacol Rep. 2024; 76(6):1256-1271.

PMID: 39333460 PMC: 11582293. DOI: 10.1007/s43440-024-00656-8.


Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy.

Miura I, Horikoshi S, Ichinose M, Suzuki Y, Watanabe K Drug Des Devel Ther. 2023; 17:3023-3031.

PMID: 37789971 PMC: 10544203. DOI: 10.2147/DDDT.S366769.


Psychopharmacology and Biological Studies of Psychosis.

Siwek M, Szewczyk B, Chrobak A Brain Sci. 2023; 13(6).

PMID: 37371334 PMC: 10296303. DOI: 10.3390/brainsci13060854.

References
1.
Rajkumar A, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob K . Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2012; 28(1):50-6. DOI: 10.1097/YIC.0b013e32835ac9da. View

2.
Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali A . Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013; 145(1-3):101-9. DOI: 10.1016/j.schres.2013.01.009. View

3.
Nucifora Jr F, Woznica E, Lee B, Cascella N, Sawa A . Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2018; 131:104257. PMC: 6395548. DOI: 10.1016/j.nbd.2018.08.016. View

4.
Harvey P, Siu C, Ogasa M, Loebel A . Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study. Schizophr Res. 2015; 166(1-3):334-8. DOI: 10.1016/j.schres.2015.06.008. View

5.
Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B . Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001; 158(4):518-26. DOI: 10.1176/appi.ajp.158.4.518. View